| Mia Danielle Debarros, MD | |
|
9040 Jackson Avenue, Joint Base Lewis Mcchord, WA 98431-1000 | |
| (253) 968-2200 | |
| Not Available |
| Full Name | Mia Danielle Debarros |
|---|---|
| Gender | Female |
| Speciality | Thoracic Surgery (cardiothoracic Vascular Surgery) |
| Location | 9040 Jackson Avenue, Joint Base Lewis Mcchord, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467783597 | NPI | - | NPPES |
| 2033450 | Medicaid | WA | |
| 26423 | Other | NE | MEDICAL LICENSE |
| 278192 | Other | MA | MEDICAL LICENSE |
| 60666886 | Other | WA | MEDICAL LICENSE |
| Entity Name | Franciscan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093165334 PECOS PAC ID: 0547173866 Enrollment ID: O20031111000789 |
News Archive
A new test using peripheral vision reaction time could lead to earlier diagnosis and more effective treatment of mild traumatic brain injury, often referred to as a concussion, according to Peter J. Bergold, PhD, professor of physiology and pharmacology at SUNY Downstate Medical Center and corresponding author of a study newly published online by the Journal of Neurotrauma.
Canada has the opportunity to be an international leader in personalized medicine and needs to invest in this area for the health of Canadians and to reap the benefits of job creation, writes Dr. Thomas Hudson in a commentary http://www.cmaj.ca/cgi/rapidpdf/cmaj.1090199 released online today in CMAJ ( Canadian Medical Association Journal ).
Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has acquired the Xtract™ Thrombus Aspiration Catheter device line from Lumen Biomedical.
Roughly half of U.S. dentists experienced verbal or reputational aggression by patients in the past year, and nearly one in four endured physical aggression, according to a new study led by researchers at NYU College of Dentistry.
Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mia Danielle Debarros, MD 9040 Jackson Avenue, Joint Base Lewis Mcchord, WA 98431-1000 Ph: (253) 968-2200 | Mia Danielle Debarros, MD 9040 Jackson Avenue, Joint Base Lewis Mcchord, WA 98431-1000 Ph: (253) 968-2200 |
News Archive
A new test using peripheral vision reaction time could lead to earlier diagnosis and more effective treatment of mild traumatic brain injury, often referred to as a concussion, according to Peter J. Bergold, PhD, professor of physiology and pharmacology at SUNY Downstate Medical Center and corresponding author of a study newly published online by the Journal of Neurotrauma.
Canada has the opportunity to be an international leader in personalized medicine and needs to invest in this area for the health of Canadians and to reap the benefits of job creation, writes Dr. Thomas Hudson in a commentary http://www.cmaj.ca/cgi/rapidpdf/cmaj.1090199 released online today in CMAJ ( Canadian Medical Association Journal ).
Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has acquired the Xtract™ Thrombus Aspiration Catheter device line from Lumen Biomedical.
Roughly half of U.S. dentists experienced verbal or reputational aggression by patients in the past year, and nearly one in four endured physical aggression, according to a new study led by researchers at NYU College of Dentistry.
Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib.
› Verified 9 days ago
John Kuckelman, Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Medicare Enrolled Practice Location: 9040 Fitzsimmons Dr, Joint Base Lewis Mcchord, WA 98431 Phone: 253-968-1110 |